Sulopenem

Sulopenem
Clinical data
ATC code	None;
Identifiers
	IUPAC name (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;
CAS Number	120788-07-0 ;
PubChem CID	9950244;
DrugBank	DB15284;
ChemSpider	8125855;
UNII	XX514BJ1XW;
KEGG	D05969;
CompTox Dashboard (EPA)	DTXSID20869656 ;
Chemical and physical data
Formula	C12H15NO5S3
Molar mass	349.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O;
	InChI InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1; Key:FLSUCZWOEMTFAQ-PRBGKLEPSA-N;

Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections in combination with probenecid (Brand name: Orlynvah). It has reached Phase III clinical trials on several occasions and continues to be the subject of ongoing research into potential applications, especially in the treatment of multiple drug resistant urinary tract infections.^[1]^[2]^[3]^[4]^[5]

Quick Facts Clinical data, ATC code ...

In October 2024, the US Food and Drug Administration approved sulopenem etzadroxil with probenecid combination for the treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited alternative oral antibiotic options. The combination was developed by Iterum Therapeutics under the trade name ORLYNVAH™.^[6]

[1]

[2]

[3]

[4]

[5]

[6]

Sulopenem

See also

References

Wikiwand - on